[2]
Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd FA, De Petris L, Di Maio M, de Marinis F. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung cancer (Amsterdam, Netherlands). 2010 Jun:68(3):319-31. doi: 10.1016/j.lungcan.2009.11.018. Epub 2009 Dec 24
[PubMed PMID: 20036027]
[3]
Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 May 1:18(9):2443-51. doi: 10.1158/1078-0432.CCR-11-2370. Epub 2012 Mar 8
[PubMed PMID: 22407829]
[4]
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27:489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9
[PubMed PMID: 22960745]
[5]
Dietel M, Bubendorf L, Dingemans AM, Dooms C, Elmberger G, García RC, Kerr KM, Lim E, López-Ríos F, Thunnissen E, Van Schil PE, von Laffert M. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. 2016 Feb:71(2):177-84. doi: 10.1136/thoraxjnl-2014-206677. Epub 2015 Nov 3
[PubMed PMID: 26530085]
[6]
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I, WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Sep:10(9):1243-1260. doi: 10.1097/JTO.0000000000000630. Epub
[PubMed PMID: 26291008]
Level 3 (low-level) evidence
[7]
Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, Harris LJ, Detterbeck FC. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May:143(5 Suppl):e211S-e250S. doi: 10.1378/chest.12-2355. Epub
[PubMed PMID: 23649440]
Level 1 (high-level) evidence
[8]
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Jul:8(7):823-59. doi: 10.1097/JTO.0b013e318290868f. Epub
[PubMed PMID: 23552377]
[9]
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine. 2018 Jan 11:378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18
[PubMed PMID: 29151359]
[10]
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. The New England journal of medicine. 2017 Feb 16:376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6
[PubMed PMID: 27959700]
[11]
Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, Besse B, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. The New England journal of medicine. 2021 Jun 24:384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4
[PubMed PMID: 34096690]
[12]
Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. The New England journal of medicine. 2022 Jul 14:387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3
[PubMed PMID: 35658005]
[13]
Peters S,Camidge DR,Shaw AT,Gadgeel S,Ahn JS,Kim DW,Ou SI,Pérol M,Dziadziuszko R,Rosell R,Zeaiter A,Mitry E,Golding S,Balas B,Noe J,Morcos PN,Mok T, Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017 Aug 31;
[PubMed PMID: 28586279]
[14]
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2018 Nov 22:379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25
[PubMed PMID: 30280657]
[15]
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ, CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. The New England journal of medicine. 2020 Nov 19:383(21):2018-2029. doi: 10.1056/NEJMoa2027187. Epub
[PubMed PMID: 33207094]
[16]
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology. 2020 Feb:21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11
[PubMed PMID: 31838007]
[17]
Planchard D, Besse B, Groen HJM, Hashemi SMS, Mazieres J, Kim TM, Quoix E, Souquet PJ, Barlesi F, Baik C, Villaruz LC, Kelly RJ, Zhang S, Tan M, Gasal E, Santarpia L, Johnson BE. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022 Jan:17(1):103-115. doi: 10.1016/j.jtho.2021.08.011. Epub 2021 Aug 26
[PubMed PMID: 34455067]
[18]
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Feb 22:378(8):731-739. doi: 10.1056/NEJMoa1714448. Epub
[PubMed PMID: 29466156]
[19]
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS, GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. The New England journal of medicine. 2020 Sep 3:383(10):944-957. doi: 10.1056/NEJMoa2002787. Epub
[PubMed PMID: 32877583]
[20]
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. The New England journal of medicine. 2020 Sep 3:383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29
[PubMed PMID: 32469185]
[21]
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2020 Aug 27:383(9):813-824. doi: 10.1056/NEJMoa2005653. Epub
[PubMed PMID: 32846060]
[22]
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA, DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. The New England journal of medicine. 2022 Jan 20:386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18
[PubMed PMID: 34534430]
[23]
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2022 May:20(5):497-530. doi: 10.6004/jnccn.2022.0025. Epub
[PubMed PMID: 35545176]
Level 1 (high-level) evidence
[24]
Berry MF, D'Amico TA, Onaitis MW, Kelsey CR. Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. The Annals of thoracic surgery. 2014 Jul:98(1):197-202. doi: 10.1016/j.athoracsur.2014.03.018. Epub 2014 May 10
[PubMed PMID: 24820392]
[25]
Murakawa T, Ichinose J, Hino H, Kitano K, Konoeda C, Nakajima J. Long-term outcomes of open and video-assisted thoracoscopic lung lobectomy for the treatment of early stage non-small cell lung cancer are similar: a propensity-matched study. World journal of surgery. 2015 May:39(5):1084-91. doi: 10.1007/s00268-014-2918-z. Epub
[PubMed PMID: 25561187]
[26]
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. The Annals of thoracic surgery. 1995 Sep:60(3):615-22; discussion 622-3
[PubMed PMID: 7677489]
Level 1 (high-level) evidence
[27]
Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (London, England). 2009 Aug 1:374(9687):379-86. doi: 10.1016/S0140-6736(09)60737-6. Epub 2009 Jul 24
[PubMed PMID: 19632716]
Level 1 (high-level) evidence
[28]
Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May:143(5 Suppl):e166S-e190S. doi: 10.1378/chest.12-2395. Epub
[PubMed PMID: 23649437]
Level 1 (high-level) evidence
[29]
Ziarnik E, Grogan EL. Postlobectomy Early Complications. Thoracic surgery clinics. 2015 Aug:25(3):355-64. doi: 10.1016/j.thorsurg.2015.04.003. Epub 2015 Jun 12
[PubMed PMID: 26210931]
[30]
Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, Jones DR, McKenna RJ, Landreneau RJ, Rusch VW, Putnam JB Jr. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. The Journal of thoracic and cardiovascular surgery. 2011 Mar:141(3):662-70. doi: 10.1016/j.jtcvs.2010.11.008. Epub
[PubMed PMID: 21335122]
Level 1 (high-level) evidence
[31]
Joo JB, DeBord JR, Montgomery CE, Munns JR, Marshall JS, Paulsen JK, Anderson RC, Meyer LE, Estes NC. Perioperative factors as predictors of operative mortality and morbidity in pneumonectomy. The American surgeon. 2001 Apr:67(4):318-21; discussion 321-2
[PubMed PMID: 11307996]
[32]
Klemperer J, Ginsberg RJ. Morbidity and mortality after pneumonectomy. Chest surgery clinics of North America. 1999 Aug:9(3):515-25, vii
[PubMed PMID: 10459427]
[33]
Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. Journal of the National Cancer Institute. 1996 Sep 4:88(17):1210-5
[PubMed PMID: 8780630]
[34]
Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. Journal of the National Cancer Institute. 2011 Oct 5:103(19):1452-60. doi: 10.1093/jnci/djr325. Epub 2011 Sep 8
[PubMed PMID: 21903745]
Level 1 (high-level) evidence
[35]
Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 May 1:28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29
[PubMed PMID: 20351327]
Level 1 (high-level) evidence
[36]
Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Jan 20:25(3):313-8
[PubMed PMID: 17235046]
[37]
Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, Nestle U, Boisselier P, Dansin E, Paumier A, Peignaux K, Thillays F, Zalcman G, Madelaine J, Pichon E, Larrouy A, Lavole A, Argo-Leignel D, Derollez M, Faivre-Finn C, Hatton MQ, Riesterer O, Bouvier-Morel E, Dunant A, Edwards JG, Thomas PA, Mercier O, Bardet A. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. The Lancet. Oncology. 2022 Jan:23(1):104-114. doi: 10.1016/S1470-2045(21)00606-9. Epub 2021 Dec 15
[PubMed PMID: 34919827]
Level 1 (high-level) evidence
[38]
Chaudhuri AA, Tang C, Binkley MS, Jin M, Wynne JF, von Eyben R, Hara WY, Trakul N, Loo BW Jr, Diehn M. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung cancer (Amsterdam, Netherlands). 2015 Jul:89(1):50-6. doi: 10.1016/j.lungcan.2015.04.014. Epub 2015 May 4
[PubMed PMID: 25997421]
[39]
Patibandla A, Featherstone C, Maclaren V, Lumsden G, Harrow S, Jones R, Chalmers AJ, McLoone P, Hicks J. Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience. Clinical oncology (Royal College of Radiologists (Great Britain)). 2020 Oct:32(10):e211. doi: 10.1016/j.clon.2020.06.006. Epub 2020 Jul 11
[PubMed PMID: 32665103]
[40]
Lodeweges JE, van Rossum PSN, Bartels MMTJ, van Lindert ASR, Pomp J, Peters M, Verhoeff JJC. Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy. Acta oncologica (Stockholm, Sweden). 2021 Aug:60(8):1061-1068. doi: 10.1080/0284186X.2021.1942545. Epub 2021 Jun 30
[PubMed PMID: 34191670]
[41]
Bogart JA, Hodgson L, Seagren SL, Blackstock AW, Wang X, Lenox R, Turrisi AT 3rd, Reilly J, Gajra A, Vokes EE, Green MR. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Jan 10:28(2):202-6. doi: 10.1200/JCO.2009.25.0753. Epub 2009 Nov 23
[PubMed PMID: 19933904]
[42]
Zhao Y, Khawandanh E, Thomas S, Zhang S, Dunne EM, Liu M, Schellenberg D. Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors. Radiation oncology (London, England). 2020 Feb 27:15(1):61. doi: 10.1186/s13014-020-01491-w. Epub 2020 Feb 27
[PubMed PMID: 32106868]
[43]
Giuliani M, Mathew AS, Bahig H, Bratman SV, Filion E, Glick D, Louie AV, Raman S, Swaminath A, Warner A, Yau V, Palma D. SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial. Clinical lung cancer. 2018 Jul:19(4):e529-e532. doi: 10.1016/j.cllc.2018.04.001. Epub 2018 Apr 18
[PubMed PMID: 29759332]
[44]
Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundapur V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, Faria S, Louie AV, Owen T, Wai E, Ramchandar K, Chan EK, Julian J, Cline K, Whelan TJ. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clinical lung cancer. 2017 Mar:18(2):250-254. doi: 10.1016/j.cllc.2016.08.002. Epub 2016 Oct 3
[PubMed PMID: 27876603]
Level 1 (high-level) evidence
[45]
Perez CA, Stanley K, Rubin P, Kramer S, Brady L, Perez-Tamayo R, Brown GS, Concannon J, Rotman M, Seydel HG. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer. 1980 Jun 1:45(11):2744-53
[PubMed PMID: 6991092]
Level 1 (high-level) evidence
[46]
Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ Jr, Choy H. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Mar 1:38(7):706-714. doi: 10.1200/JCO.19.01162. Epub 2019 Dec 16
[PubMed PMID: 31841363]
[47]
Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. International journal of radiation oncology, biology, physics. 2013 Feb 1:85(2):444-50. doi: 10.1016/j.ijrobp.2012.04.043. Epub 2012 Jun 9
[PubMed PMID: 22682812]
Level 1 (high-level) evidence
[48]
Adebahr S, Hechtner M, Schräder N, Schimek-Jasch T, Kaier K, Duncker-Rohr V, Gkika E, Momm F, Gaertner J, Becker G, Grosu AL, Nestle U. Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Mar:14(3):408-419. doi: 10.1016/j.jtho.2018.10.170. Epub 2018 Dec 3
[PubMed PMID: 30521969]
Level 2 (mid-level) evidence
[49]
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. The New England journal of medicine. 2013 Mar 14:368(11):987-98. doi: 10.1056/NEJMoa1209825. Epub
[PubMed PMID: 23484825]
[50]
Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, Mehta MP, Ryu S, Steinberg M, Timmerman R, Welsh JS, Rosenthal SA, American Society for Therapeutic Radiology and Oncology, American College of Radiology. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. International journal of radiation oncology, biology, physics. 2010 Feb 1:76(2):326-32. doi: 10.1016/j.ijrobp.2009.09.042. Epub
[PubMed PMID: 20117285]
Level 1 (high-level) evidence
[51]
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Sep 1:38(25):2830-2838. doi: 10.1200/JCO.20.00818. Epub 2020 Jun 2
[PubMed PMID: 32484754]
Level 1 (high-level) evidence
[52]
Timmerman RD, Hu C, Michalski JM, Bradley JC, Galvin J, Johnstone DW, Choy H. Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA oncology. 2018 Sep 1:4(9):1287-1288. doi: 10.1001/jamaoncol.2018.1258. Epub
[PubMed PMID: 29852036]
[53]
Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, Schiff PB, Chang G, Loo BW Jr, Bradley JD, Choy H. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA oncology. 2018 Sep 1:4(9):1263-1266. doi: 10.1001/jamaoncol.2018.1251. Epub
[PubMed PMID: 29852037]
[54]
Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, Garces YI, Pu AT, Singh AK, Videtic GM, McGarry RC, Iyengar P, Pantarotto JR, Urbanic JJ, Sun AY, Daly ME, Grills IS, Sperduto P, Normolle DP, Bradley JD, Choy H. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 May 20:37(15):1316-1325. doi: 10.1200/JCO.18.00622. Epub 2019 Apr 3
[PubMed PMID: 30943123]
[55]
Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet. Oncology. 2015 Jun:16(6):630-7. doi: 10.1016/S1470-2045(15)70168-3. Epub 2015 May 13
[PubMed PMID: 25981812]
Level 1 (high-level) evidence
[56]
Chen H, Laba JM, Boldt RG, Goodman CD, Palma DA, Senan S, Louie AV. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. International journal of radiation oncology, biology, physics. 2018 May 1:101(1):186-194. doi: 10.1016/j.ijrobp.2018.01.064. Epub 2018 Feb 3
[PubMed PMID: 29619964]
Level 1 (high-level) evidence
[57]
Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. International journal of radiation oncology, biology, physics. 2014 Nov 1:90(3):603-11. doi: 10.1016/j.ijrobp.2014.05.055. Epub 2014 Jul 19
[PubMed PMID: 25052562]
Level 1 (high-level) evidence
[58]
Palma DA, Nguyen TK, Louie AV, Malthaner R, Fortin D, Rodrigues GB, Yaremko B, Laba J, Kwan K, Gaede S, Lee T, Ward A, Warner A, Inculet R. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. JAMA oncology. 2019 May 1:5(5):681-688. doi: 10.1001/jamaoncol.2018.6993. Epub
[PubMed PMID: 30789648]
Level 1 (high-level) evidence
[59]
Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004 Oct 1:101(7):1623-31
[PubMed PMID: 15378503]
Level 2 (mid-level) evidence
[60]
Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. International journal of radiation oncology, biology, physics. 2019 Apr 1:103(5):1077-1084. doi: 10.1016/j.ijrobp.2018.11.051. Epub 2018 Dec 1
[PubMed PMID: 30513377]
Level 1 (high-level) evidence
[61]
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tomé WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Medical physics. 2010 Aug:37(8):4078-101
[PubMed PMID: 20879569]
[62]
Yaparpalvi R, Garg MK, Shen J, Bodner WR, Mynampati DK, Gafar A, Kuo HC, Basavatia AK, Ohri N, Hong LX, Kalnicki S, Tome WA. Evaluating which plan quality metrics are appropriate for use in lung SBRT. The British journal of radiology. 2018 Feb:91(1083):20170393. doi: 10.1259/bjr.20170393. Epub 2018 Jan 10
[PubMed PMID: 29227151]
Level 2 (mid-level) evidence
[63]
Kissick MW, Mackie TR. Task Group 76 Report on 'The management of respiratory motion in radiation oncology' [Med. Phys. 33, 3874-3900 (2006)]. Medical physics. 2009 Dec:36(12):5721-2
[PubMed PMID: 20095285]
[64]
Giraud P, Morvan E, Claude L, Mornex F, Le Pechoux C, Bachaud JM, Boisselier P, Beckendorf V, Morelle M, Carrère MO, STIC Study Centers. Respiratory gating techniques for optimization of lung cancer radiotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Dec:6(12):2058-68. doi: 10.1097/JTO.0b013e3182307ec2. Epub
[PubMed PMID: 22052228]
[65]
Casutt A, Kinj R, Ozsahin EM, von Garnier C, Lovis A. Fiducial markers for stereotactic lung radiation therapy: review of the transthoracic, endovascular and endobronchial approaches. European respiratory review : an official journal of the European Respiratory Society. 2022 Mar 31:31(163):. doi: 10.1183/16000617.0149-2021. Epub 2022 Jan 12
[PubMed PMID: 35022258]
[66]
Kang KH, Okoye CC, Patel RB, Siva S, Biswas T, Ellis RJ, Yao M, Machtay M, Lo SS. Complications from Stereotactic Body Radiotherapy for Lung Cancer. Cancers. 2015 Jun 15:7(2):981-1004. doi: 10.3390/cancers7020820. Epub 2015 Jun 15
[PubMed PMID: 26083933]
[67]
Wu AJ, Williams E, Modh A, Foster A, Yorke E, Rimner A, Jackson A. Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014 Aug:112(2):267-71. doi: 10.1016/j.radonc.2014.07.001. Epub 2014 Jul 23
[PubMed PMID: 25064471]
[68]
Rulach R, Ball D, Chua KLM, Dahele M, De Ruysscher D, Franks K, Gomez D, Guckenberger M, Hanna GG, Louie AV, Moghanaki D, Palma DA, Peedell C, Salem A, Siva S, Videtic GMM, Chalmers AJ, Harrow S. An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer. Advances in radiation oncology. 2021 Mar-Apr:6(2):100653. doi: 10.1016/j.adro.2021.100653. Epub 2021 Jan 20
[PubMed PMID: 33851065]
Level 3 (low-level) evidence
[69]
Wu KL, Jiang GL, Qian H, Wang LJ, Yang HJ, Fu XL, Zhao S. Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial. International journal of radiation oncology, biology, physics. 2003 Dec 1:57(5):1345-50
[PubMed PMID: 14630272]
Level 2 (mid-level) evidence
[70]
Tekatli H, Haasbeek N, Dahele M, De Haan P, Verbakel W, Bongers E, Hashemi S, Nossent E, Spoelstra F, de Langen AJ, Slotman B, Senan S. Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Jul:11(7):1081-9. doi: 10.1016/j.jtho.2016.03.008. Epub 2016 Mar 21
[PubMed PMID: 27013408]
[71]
Drodge CS, Ghosh S, Fairchild A. Thoracic reirradiation for lung cancer: a literature review and practical guide. Annals of palliative medicine. 2014 Apr:3(2):75-91. doi: 10.3978/j.issn.2224-5820.2014.03.04. Epub
[PubMed PMID: 25841506]
[72]
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Jan:11(1):39-51. doi: 10.1016/j.jtho.2015.09.009. Epub
[PubMed PMID: 26762738]
[73]
Sebio Garcia R, Yáñez Brage MI, Giménez Moolhuyzen E, Granger CL, Denehy L. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interactive cardiovascular and thoracic surgery. 2016 Sep:23(3):486-97. doi: 10.1093/icvts/ivw152. Epub 2016 May 25
[PubMed PMID: 27226400]
Level 1 (high-level) evidence
[74]
Sommer MS, Staerkind MEB, Christensen J, Vibe-Petersen J, Larsen KR, Holst Pedersen J, Langberg H. Effect of postsurgical rehabilitation programmes in patients operated for lung cancer: A systematic review and meta-analysis. Journal of rehabilitation medicine. 2018 Feb 28:50(3):236-245. doi: 10.2340/16501977-2292. Epub
[PubMed PMID: 29392334]
Level 1 (high-level) evidence